These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17725207)

  • 1. [New management of phosphocalcic abnormalities in dialysis patient].
    Delanaye P; Van Overmeire L; Dusbois BE; Krzesinski JM
    Rev Med Liege; 2007; 62(5-6):360-5. PubMed ID: 17725207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic options for mineral metabolism disorders in dialysis patients: a case report].
    Cozzolino M; Pasho S; Missaglia E; Crovetto C; Fallabrino G; Brancaccio D
    G Ital Nefrol; 2008; 25(2):234-7. PubMed ID: 18350504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of secondary hyperparathyroidism resistant to conventional therapy and tertiary hyperparathyroidism with Cinacalcet: an efficiency strategy].
    Jean G; Vanel T; Terrat JC; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Vovan C; Chazot C
    Nephrol Ther; 2010 Apr; 6(2):105-10. PubMed ID: 20185380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of six disorders of calcium and phosphorus metabolism.
    Henneman PH
    Mod Treat; 1968 Jul; 5(4):676-83. PubMed ID: 5670900
    [No Abstract]   [Full Text] [Related]  

  • 5. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
    Reichel H; Braun J
    Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
    Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
    Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progress in the treatment of secondary hyperparathyroidism. Role of calcimimetics].
    Sułowicz W
    Przegl Lek; 2006; 63 Suppl 3():3-9. PubMed ID: 16898475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
    Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
    Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S
    Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11. Vitamin D in the therapy of disorders of calcium and phosphorus metabolism.
    Kumar R; Riggs BL
    Mayo Clin Proc; 1981 May; 56(5):327-33. PubMed ID: 6262583
    [No Abstract]   [Full Text] [Related]  

  • 14. [Analysis of the efficacy and factors influencing the response of secondary hyperparathyroidism patients on hemodialysis to cinacalcet].
    Segura Torres P; Borrego Utiel FJ; Sánchez Perales MC; García Cortés MJ; Biechy Baldán MM; Pérez Bañasco V
    Nefrologia; 2010; 30(4):443-51. PubMed ID: 20651886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical application of calcimimetics].
    Nishi H; Fukagawa M
    Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of xidifon for the correction of phosphorus-calcium metabolism in patients in the terminal stage of chronic kidney failure who are on programmed hemodialysis].
    Konstantinova OV; Ianenko EK; Danilkov AP; Pashkin IN
    Urol Nefrol (Mosk); 1997; (3):23-5. PubMed ID: 9245050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.